文献リスト

1）Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-51

2）Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-88

3）Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012; 120: 2454-65

4）National Comprehensive Cancer Network. Myelodysplastic Syndromes. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Version 1.2016

5）Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89: 67-71

6）Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997; 99: 344-51

7）Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120: 1037-46

8）Nakazaki K, Nannya Y, Kurokawa M. Distribution of serum erythropoietin levels in lower risk myelo-dysplastic syndrome cases with anemia. Int J Hematol. 2014; 99: 53-6

9）Suzuki T, Oh I, Ohmine K, et al. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. Int J Hematol. 2015; 101: 32-6

10）Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini PR, Grossi A, et al. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998; 103: 1070-4

11）Thompson JA, Gilliland DG, Prchal JT, et al. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood. 2000; 95: 1175-9

12）Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004; 104: 321-7

13）Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114: 2393-400

14）Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671-4

15）Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol. 2005; 128: 204-9

16）Patton JF, Sullivan T, Mun Y, et al. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. J Support Oncol. 2005; 3: 419-26

17）Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005; 16: 1921-7

18）Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 2006; 133: 513-9

19）Giraldo P, Nomdedeu B, Loscertales J, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. 2006; 107: 2807-16

20）Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008; 142: 379-93

21）Gotlib J, Lavori P, Quesada S, et al. A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol. 2009; 84: 15-20

22）Oliva EN, Nobile F, Alimena G, et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma. 2010; 51: 1007-14

23）Villegas A, Arrizabalaga B, Fernandez-Lago C, et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin. 2011; 27: 951-60

24）Kelaidi C, Beyne-Rauzy O, Braun T, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbe-poetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol. 2013; 92: 621-31

25）Kelaidi C, Fenaux P. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond. Expert Opin Biol Ther. 2010; 10: 605-14

26）Seastone DJ, Gerds AT. Darbepoetin alfa for anemia with myelodysplastic syndrome. Expert Rev Hematol. 2015; 8: 139-46

27）Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007; 12: 1264-73

28）Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008; 87: 527-36

29）Jang JH, Harada H, Shibayama H, et al. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. Int J Hematol. 2015; 102: 401-12

30）Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998; 92: 68-75

31）Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol. 2006; 85: 174-80

32）Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009; 115: 706-15

33）Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010; 34: 1576-88

34）Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122: 2943-64

35）Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelo-odysplastic syndromes. Br J Haematol. 2014; 164: 503-25

36）Duong VH, Baer MR, Hendrick F, et al. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leuk Res. 2015; 39: 586-91

37）Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008; 111: 574-82

38）Fenaux P, Ades L. How we treat lower-risk myelo-odysplastic syndromes. Blood. 2013; 121: 4280-6

39）Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013; 27: 1283-90

40）Komrokji RS, Lancet JE, Swern AS, et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012; 120: 3419-24

41）McGraw KL, Basiorka AA, Johnson JO, et al. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelo-dysplastic syndrome progenitors. PLoS One. 2014; 9: e114249

42）Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93

43）Sibon D, Cannas G, Baracco F, et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol. 2012; 156: 619-25

44）Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5q deletion. Leukemia. 2015; in press

45）Cheson B, Greenberg P, Bennett J, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-25

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp